PharmaMar's Aplidin passes Phase III MM test

PharmaMar S.A. (Madrid:PHM) said Aplidin plitidepsin met the primary endpoint of improved progression free survival (PFS) in the Phase III ADMYRE study to treat relapsed or refractory multiple myeloma. The company plans to submit an MAA to EMA for the candidate in 4Q16.

PharmaMar said Aplidin plus dexamethasone led to a 35% lower risk of disease progression or death vs. dexamethasone alone (p=0.0054). The 255-patient study evaluated Aplidin in MM patients that had received three to six prior therapies. PharmaMar said it would present full results at an upcoming medical meeting. ...